pharma big data, david cocker
TRANSCRIPT
My Structure
• Quick heads-up on the oncology space• Evolving complexity, big science and big data
• What has changed in available data?
• Challenges for pharma (old versus new)• Enlightenment versus disentanglement• Merging new technologies with old business models• Voilà: what is possible!
Source: ASCO 2015
My three Vs
“Explosion of complexity”
The complexity of cancer treatment decisions today cannot be left in the hands of a physician only.
What does big data look like?
The era of disentanglement is upon us
Leveraging technologies for a more complete view
New data
Technologies· Ontologies· Smart algorithms· Robotics
Private data· CTMS· Impact
Tools & applications
Connected Information
· Modeling (Monte Carlo sim)· Communication platforms· Custom visualizations
· Aggregation· Data ranking· Summary statics
Application is any activity independent of the data source. It can be part of a connected process platform or independent
One challenge
Adoption
1.59 MILLION DEATHS 2012LUNG CANCER
NEED MORE PATIENTS & INVESTIGATORS
"
Investigator interest, capability, and willingness
HighLow
Lung cancer, impact per phase on top enrollment sites
Contribution top 10 organizations
Phase 1Phase 2
USA
Greece
S Korea
France
Russia
India
Australia
Canada
UK
Italy China
Spain
Poland
Bulgaria
Taiwan
Japan
Free Capacity Ratio
Almost full
Still opportunities
Bloc
ked
Germany
# site
BUSINESS QUESTIONSDesign & specifications· Current disease management· Standards of care seeking advice
Global feasibilityRecruitment assumptions
Operational choices· Country allocation· Site selection· Investigator selection
Supplementing investigator signature with claims and ethnicity data
BUSINESS QUESTIONSDesign & specifications· Current disease management· Standards of care seeking advice
Global feasibilityRecruitment assumptions
Operational choices· Country allocation· Site selection· Investigator selection
Mapping site activity by competing drugs
BUSINESS QUESTIONSDesign & specifications· Current disease management· Standards of care seeking advice
Global feasibilityRecruitment assumptions
Operational choices· Country allocation· Site selection· Investigator selection
Scenario modeling
Modeling (Monte Carlo simulation)
BUSINESS QUESTIONSDesign & specifications· Current disease management· Standards of care seeking advice
Global feasibilityRecruitment assumptions
Operational choices· Country allocation· Site selection· Investigator selection
Epidemiology
Site Properties Mapping out the big picture (Reporting)
BUSINESS QUESTIONSDesign & specifications· Current disease management· Standards of care seeking advice
Global feasibilityRecruitment assumptions
Operational choices· Country allocation· Site selection· Investigator selection
Epidemiology
Aggregated view of a high-profile clinical investigator
Would you let your kid fly a A380 without any training?